news

Our latest
Press Releases & Updates

Latest press releases

RetinAI receives FDA Clearance for Discovery, our medical image & data management platform for Ophthalmology

RetinAI today announces U.S. Food and Drug Administration (FDA) 510(k) clearance of RetinAI Discovery®, the company’s image and data management platform for next-level interoperability across the clinical and clinical study ecosystems in Ophthalmology.
read more

RetinAI attends ARVO 2022

RetinAI will attend the ARVO 2022 Annual Meeting in Denver, Colorado, from May 1st to 4th at the Colorado Convention Center. RetinAI will showcase its innovative data management and AI analysis solutions to optimize and simplify clinical development workflows for stakeholders in pharma, research and clinics. ARVO attendees who visit RetinAI at Booth #3008 will benefit from learning and seeing live demos on RetinAI Discovery for clinical studies, Discovery UNITY and RetinAI's Disease Evaluation Apps.
read more

RetinAI highlights Geographic Atrophy research with models available for analysis to enable the right decision sooner during clinical studies

RetinAI is pleased to share research findings from three published papers in Geographic Atrophy (GA). In collaboration with the Department of Ophthalmology at the University of Lausanne, Jules-Gonin Hospital, researchers at RetinAI developed a model for predicting atrophy risk in patients with non-exudative age-related macular degeneration (AMD).
read more

RetinAI announces a collaboration with Isarna Therapeutics

RetinAI Medical AG announced a collaboration with Isarna Therapeutics under which RetinAI’s IT solutions and artificial intelligence tools, including RetinAI Discovery®, shall be employed to support The BETTER Study, an international clinical trial evaluating the efficacy of ISTH0036 for neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME).
read more

Latest updates

RetinAI on the Top100 Swiss Startups [SEPTEMBER’18]

This year RetinAI has been selected as one of the TOP 100 of Swiss Startups 2018! It’s a great recognition for the team. We are proud of the results we are achieving and we are extremely excited about the future ahead!

Welcome to the new RetinAI [SEPTEMBER'18]

There's nothing permanent except change - Heraclitus. We are incredibly pleased to announce our new logo at RetinAI! This new image reflects our values, strengths and willingness to connect the anatomical and digital worlds to provide a better healthcare for the patient.

Venture Leaders China 2018 [SEPTEMBER'18]

The 10-day business roadshow in China with VentureLab is only a week away! Get to know the Venture Leaders China team member Carlos Ciller, CEO & co-founder of RetinAI before the trip begins! Source: VentureLab.

AGEFI - RetinAI [JULY'18]

RetinAI is honoured to appear in the first page of AGEFI this 5th of July! Another opportunity to highlight how advanced machine learning and artificial intelligence are changing the world of ophthalmic care for the benefit of the patient and healthcare systems worldwide.

‍

Contact us for more informations! We are happy to hear from you!

Contact Us

Ikerian AG (HQ)
‍Freiburgstrasse 3
3010 Bern
Switzerland
‍

RetinAI US Inc. (US)
6 Liberty Square
#2498 Boston, MA 02109
United States

Certifications
SolutionS For
Life Sciences & Pharma
Clinics & Hospitals
Device Manufacturers
Products
DISCOVERY
- UNITY
- For Clinical Studies
- For Clinics
REAL WORLD EVIDENCE
APPS FOR CLINICS
PRECISION MEDICINE
Contact
info@retinai.com
Media kit
Careers
Product User Manual

Imprint/Legal Notice  |  Data Processing Agreement  |  Privacy Notice  |  Created by Ikerian AG. All rights reserved 2016-2023 ©